How can CRYOPDP help Clinical Research Organizations?

Bringing a new drug to market often requires several years of preclinical and clinical research and high investment, with recent estimates calculating an average of $1335.9 million (1). 

In addition, clinical trials are becoming more complex, posing a clear risk to the pace of clinical research and the speed at which medicines are brought to patients. This increasing complexity can lead to several consequences, such as an increased burden on patients and investigators, protocol changes, increased chances of errors, higher costs and longer timelines (2). 

Complexities in Clinical Trials

Clinical Research Organizations (CROs) play a critical role in drug development as the bridge between the sponsors, the regulatory agencies and the research centres. From patient recruitment to data analysis, CROs also suffer from this increasing complexity in clinical trials. 

One of CROs’ most critical challenges is logistics. Particularly transporting investigational drugs and collection kits to clinical sites and patient samples to central labs. The success of these trials hinges on the integrity of these goods. This is where we come in. As a temperature-controlled logistics company, we play a paramount role. Ensuring optimal temperatures and timely deliveries of goods. We recognize the crucial role we play in the success of clinical trials.

At CRYOPDP, we don’t just offer temperature-controlled transport solutions for clinical trials. We understand the unique requirements of each trial, from Phase I to Phase III, and for different therapeutic areas. This understanding drives us to prioritise precision and safety when handling temperature-sensitive products. Our expert teams ensure that we provide customized solutions. These solutions guarantee the investigational drugs and patient samples’ integrity and safety. This sets us apart from our competitors.

Discover today how our temperature-controlled solutions can support clinical trials to bring innovative medicines to patients. 

References
1. Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009-2018. Jama, 323(9), 844-853.
2. Markey, N., Howitt, B., El-Mansouri, I., Schwartzenberg, C., Kotova, O., & Meier, C. (2024). Clinical trials are becoming more complex: a machine learning data analysis from over 16,000 trials. Scientific Reports, 14(1), 3514.